BackDeep Medicine Acquisition - Units (1 Ord Share Class A , 1Right) Overview

Deep Medicine Acquisition - Units (1 Ord Share Class A , 1Right) Total Liabilities

Latest total liabilities for DMAQU: $17M.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$17.09M
32.39% YoYΔ $-8.19M vs prior year quarter

Peer average / median

Loading

Deep Medicine Acquisition - Units (1 Ord Share Class A , 1Right) Total Liabilities History

Loading

Deep Medicine Acquisition - Units (1 Ord Share Class A , 1Right) vs. peers: Total Liabilities Comparison

Loading

Deep Medicine Acquisition - Units (1 Ord Share Class A , 1Right) Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Deep Medicine Acquisition - Units (1 Ord Share Class A , 1Right) (DMAQU) FAQ

The latest total liabilities for DMAQU is $17M as of March 2026. That compares with $25M in the prior-year period — down 32.4% year over year. Investors often review this figure alongside Deep Medicine Acquisition - Units (1 Ord Share Class A , 1Right)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, DMAQU's total liabilities moved from $25M to $17M — a 32.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Deep Medicine Acquisition - Units (1 Ord Share Class A , 1Right)'s operating scale or balance-sheet position.

A total liabilities figure of $17M for DMAQU is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting DMAQU's total liabilities ($17M), review year-over-year change from $25M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.